Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ibio Inc IBIO

Healthcare Biotechnology
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu... see more

Recent & Breaking News (NYSEAM:IBIO)

iBio, Inc. Receives Notice that NYSE MKT Accepted the Company's Plan to Regain Compliance with Continued Listing Standards

PR Newswire June 5, 2013

iBio Obtains New IP Protection in China

PR Newswire May 29, 2013

iBio Technology Produces Vaccine Candidate for Recently Emerged H7N9 Influenza

PR Newswire May 22, 2013

iBio, Inc. closes $4.2 million public offering and terminates At-the-market offering

PR Newswire April 29, 2013

Free Research Reports on DAL, IBIO, PHM and SWFT Issued by the Bedford Report

Marketwired April 25, 2013

iBio, Inc. Prices $4.2 Million Public Offering

PR Newswire April 23, 2013

iBio, Inc. Announces Proposed Public Offering

PR Newswire April 22, 2013

iBio Passes Commercial Technology Transfer Milestone

PR Newswire April 22, 2013

iBio, Inc. receives Notice from NYSE MKT Staff that Company currently is not in compliance with an additional Continued Listing Standard

PR Newswire April 22, 2013

GE alliance awarded contract to design new plant-based manufacturing facility in Brazil

Canada NewsWire April 9, 2013

iBio Selects Proprietary Recombinant C1 Inhibitor for Clinical Development

PR Newswire March 26, 2013

iBio Adds to iBioModulator Portfolio and Product Pipeline

PR Newswire March 13, 2013

iBio Adds New Therapeutic Antibody to Its Pipeline

PR Newswire March 4, 2013

iBio, Inc. Receives Anticipated Notice from NYSE MKT that Company is Below Certain Continued Listing Standards

PR Newswire March 4, 2013

iBio And Caliber Biotherapeutics Establish License And Collaboration Relationship

PR Newswire February 19, 2013

iBio, Inc. Receives Approval from NYSE MKT of Compliance Plan

PR Newswire February 13, 2013

iBio Announces At-the-Market Equity Offering

PR Newswire February 1, 2013

iBio Announces New Appointment to Board of Directors and New Addition to Executive Management Team

PR Newswire December 21, 2012